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Doxorubicin resistanceMany molecular mechanisms contribute to the development of doxorubicin resistance and different cancers
can express wide and diverse arrays of drug-resistance genes. The aim of this study was to identify the
changes in gene expression associated with the development of doxorubicin resistance in MCF7 breast cancer
cell line. The doxorubicin resistant MCF7 cell line was developed by stepwise selection of MCF7 cells and was
tested using the MTT assay. The alterations in gene expression were examined using the real-time based PCR
array. The ﬁndings showed an up-regulation of many phase I/II metabolizing genes, speciﬁcally, the CYP1A1
and the CYP1A2 that were up-regulated by 206- and 96-fold respectively. Drug efﬂux pump genes were also
up-regulated profoundly. TOP2A was strongly down-regulated by 202-fold. Many other changes were
observed in genes crucial for cell cycle, apoptosis and DNA repair. The ﬁndings of this project imply that
the development of doxorubicin resistance is a multi-factorial process.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
Breast cancer is a serious global health problem being the second
most common of all cancers and by far the most frequent cancer
amongst women [1]. Doxorubicin is a naturally occurring anthracycline
antibiotic [2] that is an essential component of many treatment regi-
mens for solid and blood tumors [3], and it is broadly considered the
most active single agent available for the treatment of breast cancer
[4]. Doxorubicin induces cancer cell death by many mechanisms, most
importantly is topoisomerase II-α (TOP2A) poisoning [5].
Although breast cancer is considered one of the most chemo-
sensitive solid tumors, most initially responsive tumors relapse and
develop resistance to a broad spectrum of drugs. Consequently, breast
cancer becomes refractory to cytotoxic drugs and is typically incur-
able [6]. Response rates to single doxorubicin treatment range from
43% in previously untreated patients to 28% in patients previously ex-
posed to the drug [7], which indicate that growing resistance to doxo-
rubicin can lead to an unsuccessful outcome in nearly 50% of treated
patients, making resistance a major cause of treatment failure.
Two forms of resistance to chemotherapy have been described: in-
trinsic and acquired resistance. Intrinsic resistance is a pre-existing
resistance that present prior to the exposure to a given drug. In con-
trast, acquired resistance develops in tumors that were initially sensi-
tive to the drug, after the exposure to this drug [8]. Drug resistance is
a manifestation of cancer. The somatic mutations and genomic plas-
ticity associated with cancer are the foundation of drug resistance
[9]. Therefore, cancer heterogeneity explains the fact that everyrights reserved.cancer expresses a different array of drug-resistance genes, and
even cells within the same cancer, can exhibit enormous amount of
heterogeneity with respect to drug resistance [10]. Manymechanisms
could work simultaneously to protect cancer cells from chemothera-
peutic agents such as doxorubicin [11]. The most frequently identiﬁed
molecular changes in doxorubicin resistance are decreased intracellu-
lar concentration of the drug due to the expression of many mem-
brane efﬂux pumps [12], increased drug metabolism enzymes such
as glutathione S-transferase GST [13], reduced concentration and ac-
tivity of TOP2A [14], and failure of the cellular apoptotic pathways
[15].
Since multidrug resistance is a multi-factorial phenomenon, a large-
scale expression analysis of drug resistant cells may provide informa-
tion about new candidate genes that could contribute to the develop-
ment of resistance [16]. In this study we identiﬁed the changes in
gene expression associated with the development of doxorubicin-
resistant phenotype in breast cancer cell line MCF7, employing the po-
lymerase chain reaction (PCR) array technology (RT2 Proﬁler™ PCR
Array). The PCR array is a 96-well plate containing primers for a set of
84 genes involved in different cellular processes; to the best of our
knowledge this is the ﬁrst study that used the real time PCR array in
studying doxorubicin resistance in breast cancer cell lines.2. Results
2.1. Establishment and characterization of the MCF7/D320 cells
The doxorubicin resistant MCF7/D320 cell line was established
after six sequential treatments with a 320 nM ﬁnal concentration of
doxorubicin.
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In order to identify changes in gene expression in breast cancer
cells that correlate with the establishment of resistance to doxorubi-
cin, the sensitivity of the MCF7/D320 and the MCF7/WT cells to doxo-
rubicin was compared.
According to the MTT assay results, the MCF7/D320 cells exhibited
considerable resistance to the corresponding drug. The relative resis-
tance of MCF7/D320 cells, as compared to the MCF7/WT, is demon-
strated in Fig. 1. The IC50 values for MCF7/D320 and MCF7/WT were
4134.5±9.2 nM (mean±STD) and 286.2±7.2 nM (mean±STD), re-
spectively. The degree of resistance is evaluated in terms of resistance
index (R) which is calculated according to the relation: R=IC50 resis-
tant cells/IC50 sensitive cells. Therefore, the MCF7/D320 cells were ap-
proximately 14-fold more resistant to doxorubicin than the original
cell line.
2.3. Morphological features
The development of the drug resistance phenotype is accompa-
nied by changes in different biological features of the malignant
cells, including morphological ones.
When compared to MCF7/WT, the MCF7/D320 cells were larger
with less deﬁned irregular, rounded shape and contained multiple
nuclei in the cytoplasm. Multiple, relatively large vesicles were also
observed in the cytoplasm. The shape of MCF7/WT and MCF7/D320
cells is shown in Fig. 2.
2.4. Intracellular doxorubicin analysis
Fluorescent cell imaging was used to determine intracellular doxo-
rubicin localization and accumulation in MCF7/WT and MCF7/D320
cells. In the MCF7/WT cells doxorubicin was speciﬁcally concentrated
in the nuclei. Conversely, MCF7/D320 cells showed no obvious ﬂuores-
cence in their nuclei. Instead, multiple ﬂuorescent vesicles were ob-
served in the cytoplasm of the resistant cells; these vesicles were
located preferentially around the nuclei; the high ﬂuorescence indicates
that these vesicles were ﬁlled with high concentration of doxorubicin
(Fig. 3).
2.5. Gene expression changes upon selection for doxorubicin resistance
In order to identify genes and pathways important in the develop-
ment of drug resistance, a gene expression proﬁling analysis was
performed using the PCR array, as described in Materials and
methods. To ﬁlter out unreliable data and identify genes with signiﬁ-
cantly different expression, a standard 3-fold change in expression
was used as an arbitrary cut-off. Expression analysis revealed signiﬁ-
cant changes of 41 genes (49%), out of the 84 genes examined, in the
MCF7/D320 cells compared to the MCF7/WT cells, Fig. 4. Twenty-sevenFig. 1. The logarithmic curves for the response of MCF7/D320 cells to doxorubicin as
compared to response of MCF7/WT cells.of these genes (66%) were up-regulated (Table 1.A), and 14 genes
(34%) were down-regulate (Table 1.B).
2.6. Gene ontology and pathways analysis
Gene ontology categories for both up-regulated and down-
regulated genes are shown in Table 2. The data are demonstrating
that the selection for doxorubicin resistance led to overall changes
in the patterns of gene expression, including mainly metabolism,
transport, cell cycle, apoptosis and DNA repair. The most important
pathways in which the up-regulated and the down-regulated genes
participate in are presented in Table 3.
3. Discussion
The development of resistance towards doxorubicin in the MCF7
cells was accompanied by unique morphological changes. The resistant
cells exhibited the presence of multiple nuclei in the cytoplasm,
according to Yang et al. [19]; this observation was attributed, mostly,
to increased cellular fusion between the cells under continuous doxoru-
bicin stress. Additionally, many large vesicles were observed in the cy-
toplasm of resistant cells. These vesicles, when observed under the
ﬂuorescent microscopy, were found to be ﬁlled with doxorubicin and
were clustered preferentially around the nuclei (Fig. 3). Chen et al.
[20] suggested that the cells sequester the drug into these vesicles to
avoid doxorubicin poisoning effect on theDNA, and to help in the extra-
cellular clearance of the drug outside the cell. Moreover, Rajagopal and
Simon [21] have suggested that these vesicles may play a role in the
metabolic inactivation of doxorubicin, because of the high concentra-
tion of MRP transporters that was observed in the membranes of
these vesicles. The MRP transporters are known to transport the
inactivated glutathione-conjugated doxorubicin molecules.
One of the most common changes in doxorubicin resistance is the
up-regulation of many transporters genes [12]. This up-regulation ex-
plains the reduced intracellular doxorubicin concentration inside the
resistant cells that was observed in the intracellular drug analysis
(Fig. 3).
The ABCB1 gene, which encodes the P-gp, was the most up-
regulated transporter gene by 24-fold. The P-gp is broad-spectrum
multidrug efﬂux pump that is considered to be a major contributor
to the development of multidrug resistance [12,22]. Moreover, two
genes of the ABCC family, which encodes the MRP transporters,
were also profoundly changed, namely ABCC2 (MRP2) by 16.4-fold
and ABCC6 (MRP6) by 6.2-fold. Both of these transporters have also
been detected in doxorubicin resistant cell lines [23,24].
Another ﬁnding on the transporters gene expression level was the
up-regulation of the ABCG2 gene, which encodes the BCRP, by
15.9-fold in the resistant cells. Several studies have shown that this
transporter was over-expressed in doxorubicin resistant cells [25].
Finally, the MVP gene that encodes the LRP was up-regulated by
13.9-folds. The LRP is a non-ATP-dependent intra-cellular transporter,
which is responsible for the drug efﬂux from the nucleus [26]. This
up-regulation may be linked to the reduced accumulation of doxoru-
bicin in the nuclei of the MCF7/D320 cells that was observed in the in-
tracellular doxorubicin analysis (Fig. 3).
The TOP2A is the primary target for doxorubicin mechanism of ac-
tion [5]. Thus, resistance to doxorubicin has been correlated reduction
in quantity and quality in TOP2A activity [27]. Therefore, the massive
reduction in the expression levels of TOP2A gene in the PCR array pro-
ﬁling data by 202.6-fold in MCF7/D320 cells was an expected ﬁnding.
Interestingly, no considerable changes were observed in the expres-
sion levels of the other topoisomerase isomers, TOP1 and TOP2B.
This selective down-regulation of the expression of TOP2A suggests
a preferential activity of doxorubicin on the alpha isomer.
Many cytochrome P450 enzymes including CYP1A1, CYP1A2,
CYP2C19, CYP2B6, CYP2C9, CYP3A4 and CYP3A5 were up-regulated
Fig. 2. Comparison of the morphology of MCF7/WT and MCF7/D320. MCF7/WT cells appear small, spindle-shaped cells with single nucleus. MCF7/D320 cells appear large, irregular,
rounded cells with multiple nuclei (highlighted by the yellow circles) and multiple vesicles (highlighted by the red circles). A and B, higher magniﬁcation.
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CYP1A2 genes were 206.1-fold and 96.2-foldup-regulated, respective-
ly. Most of the studies concerning the relationship between doxorubi-
cin and the CYP450 enzymes were conducted mainly on cardiac cell
lines; therefore limited data are available concerning the effect of
doxorubicin on the expression of these enzymes in cancer cells.
Volkova et al. [28] concluded that the exposure of cardiac cells to
doxorubicin increased the expression of many metabolizing enzymes
including CYP1A1 and CYP1A2. This up-regulation was considered a
protective response against doxorubicin cardiac toxicity. Likewise,the reported high up-regulation of these enzymes in the results of
the current study could be regarded as an important resistant mech-
anism, which has been induced to deactivate doxorubicin and there-
by increase the cell survival chances.
Additionally, the CYP3A4 (10.5-fold) and CYP3A5 (6.7-fold) gene
expression levels were found to be up-regulated in the resistant
cells. Rodriguez-Antona and Ingelman-Sundberg [29] suggested that
tumor cells expressing high CYP3A enzymes showed low response
to doxorubicin. This ﬁnding was related to the CYP3A oxidation role
in the doxorubicin metabolic process.
Fig. 3. Fluorescent microscopy images of MCF7/WT and MCF7/D320. MCF7/WT cells: High ﬂuorescence is seen inside the nuclei indicating high concentration of doxorubicin. MCF7/D320
cell: (A) Very low ﬂuorescent both in the cytoplasm and in the nuclei of the cells. Fluorescent vesicles are seen indicating that these vesicles are doxorubicin-ﬁlled. (B) A closer view dem-
onstrates the doxorubicin-ﬁlled vesicles.
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CYP2B6 (22.4-fold), and CYP2C9 (7.4-fold) were also up-regulated
in MCF7/D320. It is worth noting that an up-regulation of manyFig. 4. Scatter plots of genes with altered expression. Up-regulatCYP450 genes was also observed clinically in two studies that
addressed the resistance towards cyclophosphamide and doxorubicin
combination regimen. However, the authors assumed that theed genes are in red and down-regulated genes are in green.
Table 1
Up-regulated (A) and down-regulated (B) genes in MCF7/D320.
A B
Gene symbol Fold regulation Gene symbol Fold regulation
CYP1A1 206.1 TOP2A −202.6
CYP1A2 96.1 BRCA2 −35.8
CYP2C19 34.0 BRCA1 −16.7
ABCB1 (P-gp) 24.0 ESR1 −7.5
CYP2B6 22.4 DHFR −7.3
ABCC2 (MRP2) 16.4 TP53 −5.9
ABCG2 (BCRP) 15.8 MYC −5.3
GSTP1 14.2 CCNE1 −4.8
ERBB4 13.8 RARA −4.5
MVP (LRP) 12.8 CDK2 −4.0
NAT2 12.8 CDKN1B (p27) −3.8
CYP3A4 10.4 MET −3.2
SULT1E1 10.4 GSK3A −3.2
CDKN1A (p21) 9.4 ATM −3.1
CYP2C9 7.4
CDKN2A (p14) 7.1
CYP3A5 6.7
FGF2 6.7
ABCC6 (MRP6) 6.2
NFKBIE 6.2
AHR 6.0
EPHX1 5.8
RXRA 5.2
RXRB 4.7
BCL2 4.3
IGF1R 3.8
ESR2 3.1
Table 3
Pathway analysis for up-regulated genes in MCF7/D320.
Pathway Count Genes
Pathway analysis for up-regulated genes in MCF7/D320
Drug metabolism 10 CYP2B6, CYP3A5, CYP2C19, GSTP1, CYP2C9,
CYP1A2, NAT2, CYP3A4, EPHX1, SULF1E1
Pathways in cancer 8 CDKN1A, IGF1R, FGF2, RXRB, BCL2, GSTP1,
CDKN2A, RXRA
Transporters 5 ABCB1, ABCG2, ABCC2, ABCC6, MVP
Cell cycle: g1/s check point 2 CDKN1A, CDKN2A
Pathway analysis for up-regulated genes in MCF7/D320
Pathways in cancer 8 MYC, MET, RARA, CDK2, CDKN1B, CCNE1,
BRCA2, TP53
Cell cycle 6 MYC, CDK2, CDKN1B, CCNE1, TP53, ATM
p53 signaling pathway 4 CDK2, CCNE1, TP53, ATM
DNA repair 3 ATM, BRCA1, BRCA2
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nism of resistance against cyclophosphamide rather than doxorubicin
[30]. This conclusion was built on the documented fact that cyclo-
phosphamide is inactivated by these enzymes, whilst limited data re-
garding role in doxorubicin deactivation are available.
A profound up-regulation of the expression of the GSTP1 gene
(14.3-fold) was also observed in resistant cells. The GSTP1, a phase
II metabolizing enzyme, catalyses the conjugation of glutathione to
a wide variety of drugs, rendering them more water-soluble, therebyTable 2
Gene ontology groups for up/down-regulated genes (≥3-fold) in MCF7/D320.
Category Count Genes
Gene ontology groups for up -regulated genes (≥3-fold) in MCF7/D320
Metabolic process 19 EPHX1, NAT2, GSTP1, ABCC6, CDKN2A,
RXRA, CYP1A1, CYP1A2, AHR, ERBB4,
IGF1R, CYP3A5, CYP2B6, SULT1E1, FGF2,
RXRB, CYP2C19, BCL2, CYP2C9
Regulation of cell proliferation 7 CDKN1A, IGF1R, ERBB4, FGF2, BCL2,
CDKN2A, RXRA
Regulation of programmed cell
death
7 CDKN1A, IGF1R, FGF2, BCL2, GSTP1,
CDKN2A, RXRA
Transmembrane transport 5 ABCB1, ABCC2, ABCC6, ABCG2, MVP
Response to cyclic organic
substances
5 CDKN1A, EPHX1, BCL2, RXRA, CYP1A1
Positive regulation of gene
expression
4 AHR, FGF2, RXRB, RXRA
Gene ontology groups for down -regulated genes (≥3-fold) in MCF7/D320
Regulation of transcription,
DNA-dependent
9 BRCA1, MYC, RARA, ESR1, CDKN1B,
CCNE1, BRCA2, TP53, ATM
Regulation of cell cycle 7 BRCA1, MYC, CDK2, CDKN1B, BRCA2,
TP53, ATM
Regulation of apoptosis 7 BRCA1, MYC, TOP2A, CDKN1B, BRCA2,
TP53, ATM
Regulation of cell proliferation 6 BRCA1, MYC, CDK2, CDKN1B, BRCA2,
TP53
Regulation of cellular
metabolic process
5 BRCA1, GSK3A, CDKN1B, BRCA2, TP53
DNA repair 5 BRCA1, TOP2A, BRCA2, TP53, ATMfacilitating their elimination from the cell [31]. Expression of GSTP1
has been correlated with acquired resistance to doxorubicin [13].
Importantly, the up-regulation of the GSTP1gene expression is com-
monly accompanied by an up-regulation of the expression of the
MRP (ABCC) transporters that expel the resultant doxorubicin-
glutathione conjugates [32].
Additionally, the results showed that the EPHX1 gene was up-
regulated in MCF7/D320 cells by about 5.8-fold. The EPHX1enzyme in-
activates many reactive species [33]. Hence, the up-regulation of this
enzyme could enhance the resistance by inactivating the doxorubicin
induced reactive species and reducing free radical formation. A simi-
lar ﬁnding was reported by Kudoh et al. [34], who observed an in-
crease in the expression of this enzyme in doxorubicin resistant cells.
There was also a 10.5-fold increase in sulfotransferase (SULT1E1)
gene expression level in MCF7/D320 cells. Cowan et al. [35] found an
increase in the enzymatic activity of this enzyme in MCF7 cells resis-
tant to doxorubicin. Finally, the expression level of another metabo-
lizing enzyme, the N-acetyltrasferase 2 (NAT2), was elevated by
12.9-fold. This enzyme catalyzes the acetylation reaction of several
aryl-amine and hydroxyl-amine xenobiotics [36].
The mRNA levels of many apoptotic pathway genes showed pro-
found alterations. The TP53 gene was down-regulated by 5.9-fold,
while the CDKN1A (p21) gene, a major inhibitor of p53-dependent
apoptosis [37], was up-regulated by 9.4-fold. Bunz et al. [38] found
that expression of p21 protects cells from doxorubicin-induced apo-
ptosis. Another upstream protein that regulates the p53 is the ataxia
telangiectasia mutated (ATM) gene that was down-regulated by
3-fold. The ATM selectively activate p53, providing a mechanism for
controlling cell cycle and apoptotic responses [39], so the up-
regulation of the p21 gene and the down-regulation of the ATM
gene will further suppress the p53 pathway.
Another important alteration in the apoptotic pathway was the
up-regulation of the BCL2 gene by 4.3-fold. The BCL2 is a potent
anti-apoptotic protein [40]. The up-regulation of the expression of this
gene is known to promote cell survival and has been correlated with
the development of doxorubicin resistance [15]. Moreover, the BCL2/
BAX (BCL2-associated X protein) ratio was high in the MCF7/D320
cells, as the BCL2 was up-regulated while the BAX level was almost
unchanged. This ratio is a major indicator of the cell apoptotic fate [41].
Down-regulation of the expression of the glycogen synthase
kinase-3 (GSK3) gene in MCF7/D320 cells by 3.1-fold was also observed.
The product of this gene is a multi-tasking serine/threonine kinase
known to regulate critical cellular functions such as gene expression,
mobility, and apoptosis [42]. Studies have shown that the inhibition of
GSK3 delays the apoptotic signaling pathway and thereby induces resis-
tance to chemotherapeutic agents, such as camptothecin, etoposide,
and doxorubicin [42]. Therefore, the observed GSK3 gene down-
regulation can be considered as an additional effort exhibited by the
cells to escape doxorubicin-induced apoptosis.
218 S. AbuHammad, M. Zihlif / Genomics 101 (2013) 213–220Finally, the nuclear factor-kappa-B inhibitor (NFKBIE) genewas up-
regulated by 6.2-fold. The nuclear factor-kappa-B (NFκB) plays an im-
portant role in regulating the expression of anti-apoptotic proteins
[43]. Paradoxically, increasing NFKBIE expression might be expected to
deactivate NFκB, thereby reducing expression of anti-apoptotic proteins
and rendering cells more sensitive to doxorubicin. Whether the in-
creased expression of NFKBIE observed in MCF7/D320 cells is important
for doxorubicin resistance requires further study.
The changes in the gene expression proﬁles of the doxorubicin re-
sistant cells involved many cell cycle controlling genes. Both CDK2
and its target cyclin E (CCNE1) genes have been down-regulated in
MCF7/D320 cells by 4.7- and 4-fold, respectively. The cyclin E/CDK2
complex is a crucial regulator of the G1/S transition [44]. Further-
more, the results showed alterations in the expression levels of
CDKN1A (p21) and CDKN1B (p27) genes, which are inhibitors of the
cyclin E/CDK2 complex [45]. CDKN1A was up-regulated by 9.4-fold,
while CDKN1B was down-regulated by 3.7-fold; therefore it is clear
that the cell is going more towards inhibiting the cyclin E/CDK2 com-
plex. Another ﬁnding was the up-regulation of the expression level of
CDKN2A (p16) by 7.1-fold. The p16 regulates the G1/S cell cycle tran-
sition, and has the capacity to arrest cells in the G1-phase [46]. Taken
together, these changes in the cell cycle genes indicate that the resis-
tant cells are trying to postpone the entrance into the S-phase in an
attempt to prohibit doxorubicin from exerting its toxic effect.
Finally, the myelocytomatosis (MYC) transcription factor gene ex-
pression level was also decreased by 5.3-fold. The c-Myc has the abil-
ity to promote cell proliferation [47]. A study by Grassilli et al. [48]
found that the absence of Myc impairs the apoptotic response to
doxorubicin, thus conferring resistance to this drug.
The DNA repair genes, BRCA1 and BRCA2, are well-established breast
cancer susceptibilitymarkers. These genes can serve as predictors of the
response to chemotherapies that induce DNA damage [18]. BRCA1 and
BRCA2 expression levels have been down-regulated in MCF7/D320 cells
by 16.7- and 35.8-fold, respectively. There are great discrepancies in
the studies that addressed the role of BRCA1 and BRCA2 proteins in
doxorubicin resistance. Some studies found that absence of BRCA1
was accompanied by increased resistance to doxorubicin [4,18], whilst
others found that tumor cells with low BRCA1 were highly sensitive to
doxorubicin [49]. De Luca et al. [50] suggested that BRCA1 may have a
role as a co-regulator in the transcriptional level, and found that
BRCA1 mediates apoptosis and decreases viability in response to doxo-
rubicin treatment in prostate cancer, it had also been concluded that
loss of BRCA1 resulted in increased resistance towards doxorubicin.
Consequently, the profound down-regulation of BRCA1 and BRCA2
gene expression level seen in MCF7/D320 cells may be considered as
one of the main changes towards gaining the resistant phenotype.
4. Conclusions
In conclusion, changes in gene expression levels that accompany
the establishment of doxorubicin resistance, in MCF7 breast cancer
cells, were identiﬁed in a collective view. The ﬁndings of this project
provide important insights into the possible biochemical pathways
that enable breast cancer cells to acquire resistance to doxorubicin,
such as the metabolic pathways, the drug efﬂux pathways, the apo-
ptotic pathways, the cell cycle pathways, and the DNA repair path-
ways. In addition to alteration in TOP2A, that is the main target for
doxorubicin.
5. Materials and methods
5.1. Cell culture growth conditions
The MCF7 cell line, originally obtained from the American Type
Culture Collection (ATCC; USA), was kindly provided by the Molecu-
lar Biology Laboratory, University of Jordan. The MCF7 cells weremaintained as an attached monolayer culture in the commercially
deﬁned RPMI 1640 medium (HyClone, USA), supplemented with
10% (v/v) heat-inactivated fetal bovine serum (FBS) (HyClone,
USA), 2 mM L-glutamine, 100 U/mL and 100 μg/mL penicillin–
streptomycin (HyClone, USA), and 25 μM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) (Lonza, USA).
The cells were grown on either 25 or 75 cm2 attached types,
ﬁlter-cap culture ﬂasks (NunClon, Denmark). The cells were then in-
cubated at 37 °C in a 90% humidiﬁed atmosphere of 5% CO2.
5.2. Establishment of doxorubicin resistant sub-line
Doxorubicin 2 mg/mL (Ebewe, Austria) was used to induce resis-
tance in the MCF7 cells. To resistant cells were selected by stepwise
selection method [17]; initially the cells were grown in a cell culture
media containing a doxorubicin concentration of 10 nM. When the
cells were capable of growing and reaching appropriate conﬂuency
at a certain concentration, the cells were passaged and double the
previous doxorubicin concentration was used for stepwise selection
of resistant cells; a ﬁnal concentration of 320 nM doxorubicin was
applied.
The developed sub-line is regarded as MCF7/D320, and the wild
type (untreated control) MCF7 as MCF7/WT through this paper. To
exclude the effects associated with long-term culture of MCF7 cells,
the MCF7/WT cells were cultured under identical conditions and
maintained in culture for the same period of time as the MCF7/D320
cells but in the absence of doxorubicin.
Before any further experiment, theMCF7/D320 cellsweremaintained
in doxorubicin free medium for at least 2 days.
5.3. Cell proliferation assay
The antiproliferative effects of doxorubicin on MCF7/WT and
MCF7/D320 cells were evaluated using the CellTiter Non-Radioactive Cell
Proliferation Assay Kit® (Promega, USA), according to manufacturer's in-
structions. This assay is a colorimetric test based on the reduction of
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT),
a yellow tetrazole, to a purple formazan, a process that occurs in the mi-
tochondria of viable cells.
The cells were seeded onto 96-well plates (Greiner, Germany) at a
concentration of 10×103 cells/well and incubated for at least 18 h.
After which, horizontal dilutions of the drug ranging from 40 to
1000×103 nM were added (100 μL/well). Each concentration was
added in duplicates, and every plate contained a control of cells in
plain medium. The cells were then incubated at 37 °C for 72 h.
After incubation, the media were aspirated from the wells and re-
placed by fresh media (100 μL/well); 15 μL of the MTT dye solution
was added to each well. The plates were incubated at 37 °C for 4 h,
and then 100 μL of solubilisation/stop solution was added to each
well. Optical density (OD) at 570 nm wavelength was recorded 1 h
later using a 96-well plate reader (Sunrise basic sciences, Austria).
Measurements were performed in duplicates.
5.4. Data analysis
Results of the MTT cell proliferation assay were analyzed using the
GraphPad PRISM®5.0 software (GraphPad Software, Inc.). The inhib-
itory concentration (IC50) values, which are the drug concentration
at which 50% of cells are viable, were calculated from the logarithmic
trend line of the cytotoxicity graphs.
5.5. Analysis of intracellular doxorubicin
The distribution of doxorubicin associated with both the MCF7/WT
and the MCF7/D320 cells was assessed based on the inherent ﬂuores-
cence of doxorubicin [18].
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cubation, cells were washed with cold PBS buffer and immediately run
on a ﬂuorescentmicroscope (Nikon, USA). Doxorubicinmolecules asso-
ciated with the cells were excited with an argon laser beam at 488 nm,
and the emitted ﬂuorescence was detected through 575 nm band pass
ﬁlter.
5.6. RNA isolation
The RNAwas isolated using an RNeasy®Mini kit (Qiagen, Germany)
following the manufacturer's instructions. An RNase-free DNase set
(Qiagen, Germany) was used according to the manufacturer's in-
structions to ensure complete genomic DNA elimination. Purity of
isolated RNA was determined by measuring ratio of the optical den-
sity of the samples at 260 and 280 nm. The OD260/OD280 ratio was
ranging from 1.9 to 2.2 for all samples. Denaturing agarose gel elec-
trophoresis was used for the visualization of the intactness of the iso-
lated RNA.
5.7. cDNA synthesis
Complementary DNA strands were synthesized using RT2 First
Strand kit (Qiagen, Germany), according to the manufacturer's
instructions; aliquots containing 1 μg of total RNA were used from
each sample. The OD260/OD280 ratio was calculated for purity and it
was within 1.8–2.0.
5.8. Gene expression proﬁling
Pathway-focused gene expression proﬁling was done using a
96-well human cancer drug resistance and metabolism PCR array, RT2
Proﬁler PCR array (PAHS-004A, Human Cancer Drug Resistance & Me-
tabolism PCR Array, Qiagen, USA). In this array, 84 wells contained all
the components required for the PCR reaction in addition to a primer
for a single gene in each well. These genes are involved in the body re-
sponse to chemotherapy, and encode important enzymes that contrib-
ute in drug resistance, metabolism, DNA repair, cell cycle, growth
factors, hormone receptors, and transcription factors.
Before performing the procedures all the surfaces, plastic- and
glassware were wiped down with RNaseZap® in order to eliminating
RNase contamination.
A diluted cDNA aliquot, equivalent to 1 μg total RNA for each plate,
was mixed with the RT2 SYBR® green master mix (Qiagen, USA)
according to the manufactures instructions, and loaded onto the
96-well array. Real-time PCRwas performed using the iCycler (Bio-Rad,
USA) thermo-cycler, by heating the plate to 95 °C for 10 min, followed
by 40 cycles of 95 °C for 15 s and 60 °C for 1 min.
5.9. Data analysis
The cycle threshold (Ct) values for each sample were given auto-
matically by the iCycler according to the ampliﬁcation curves. The
baseline and threshold values were manually set as recommended
by the PCR array user manual. The selected threshold was 20.0 and
the baseline cycles are 2–10.
The PCR array data analysis was performed using the ΔΔCt meth-
od (delta delta cycle threshold); the analysis was performed
automatically according to the SABiosciences company (Qiagen,
USA) web portal (www.SABiosciences.com/pcrarraydataanalysis.
php), and further re-calculated manually. Changes in gene expres-
sion were illustrated as a fold increase or decrease. The data were
normalized, across all plates, to the following housekeeping genes:
hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal pro-
tein L13a (RPL13A), glyceraldehydes-3-phosphate dehydrogenase
(GAPDH) and, actin beta ACTB. The threshold cycle values of thecontrol wells were all within the ranges recommended by the PCR
array user manual.
5.10. Gene functional annotation
The genes whose expression levels were altered by ≥3-fold were
classiﬁed according to the web-based bioinformatics software, the
Database for Annotation, Visualization and Integrated Discovery
(DAVID) gene annotation website, http://david.abcc.ncifcrf.gov/,
which provides biological classiﬁcation of the genes according to
their cellular function and the pathways in which they participate.
Results are displayed in comparative tables that describe the most
affected biological function by genes changes. By this means, it was
possible to identify the biological pathways that were most disturbed
by doxorubicin resistance, which could provide clues to the mecha-
nisms by which the cells can develop resistance against doxorubicin.
For pathway analysis, two different databases were employed
using DAVID, the Kyoto Encyclopedia of Genes and Genomes
(KEGG) and the Biocarta databases.
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